Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Opdivo/Yervoy Combo Approved for First-Line NSCLC Treatment in South Korea: Ono
December 18, 2020
- Taiho Gains Non-Exclusive Rights to Use PeptiDream’s Drug Discovery Platform
December 18, 2020
- Lenvima/Keytruda Pair Hits Survival Goal in Advanced Endometrial Cancer
December 17, 2020
- Kobayashi Kako Manually Managed Itraconazole Production; Hand-Written Record on Rilmazafone Mix-Up Found
December 17, 2020
- Takeda’s Eosinophilic Esophagitis Med Gets Priority Review in US
December 17, 2020
- Daiichi Sankyo CEO Says Lead ADC Projects on Track, Eager to Boost Portfolio
December 17, 2020
- Shionogi Kicks Off Japan PI/PII Study of COVID-19 Vaccine Candidate
December 17, 2020
- Industry Sees Flip-Flops on Supplies of Kobayashi Kako-Made Products
December 16, 2020
- UCB Japan to Independently Market New Products; Stand-Alone E Keppra Sales “Going Smoothly”: President
December 16, 2020
- MSD’s Zerbaxa Being Recalled, Shipments Halted after It Fails Sterility Testing
December 16, 2020
- Lorbrena Filed as 1st Line Therapy for ALK-Positive Lung Cancer: Pfizer
December 16, 2020
- PIII Trial Launched for DS-1062 in NSCLC: Daiichi Sankyo/AZ
December 16, 2020
- Efient Filed for Label Expansion to Prevent Ischemic Stroke Recurrences
December 16, 2020
- Ono Licenses MALT1 Inhibitor for Blood Cancer Treatments from Takeda Spin-Off Chordia
December 16, 2020
- Filing for SanBio’s Sakigake Cell Therapy for TBI Likely to Be Delayed
December 16, 2020
- Solasia’s Peripheral Neuropathy Drug Fails in PIII in Colorectal Cancer Patients
December 16, 2020
- Pfizer, Life Data Initiative, NTT Data Tie Up on Big Data Research on Cancer Outcome Evaluation
December 15, 2020
- Enhertu Gets CHMP Backing for HER2-Positive Breast Cancer
December 15, 2020
- Kobayashi Kako Temporary Halts Shipments of All Products after Tainted Itraconazole Issue
December 15, 2020
- Forxiga Filed for Chronic Kidney Disease in Japan: AZ
December 15, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…